RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
Rhea-AI Summary
RenovoRx (NASDAQ: RNXT) will present new clinical data on February 6, 2026 at the SIO Annual Scientific Meeting showing that the TAMP™ therapy platform can use a simplified external pressure transducer to obtain reliable intra-arterial pressure measurements during double-balloon RenovoCath procedures.
The study (Abstract 303) showed strong correlation to intravascular pressure wire measurements in a porcine model and found peak pressure is affected by controllable variables like balloon spacing and target vessel diameter, highlighting procedural optimization opportunities.
Positive
- Presentation scheduled at SIO on Feb 6, 2026 (Abstract 303)
- Study shows strong correlation between external transducer and intravascular pressure wire in a porcine model
- Findings identify procedural variables (balloon spacing, vessel diameter) that can optimize drug delivery
Negative
- Results are from a porcine model and not human clinical outcome data
- No data reported showing improved patient clinical outcomes or survival
News Market Reaction
On the day this news was published, RNXT declined 4.50%, reflecting a moderate negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $37M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data flags only one peer stock (IPSC) moving down ~4.79% with no news, while other biotech peers show mixed moves. This points to stock-specific drivers rather than a coordinated sector move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | SIO abstract acceptance | Positive | +0.2% | Acceptance of TAMP intravascular pressure ePoster at SIO 2026. |
| Jan 08 | ASCO GI data | Positive | +13.9% | Promising TIGeR-PaC PK/PD sub-study data with reduced systemic exposure. |
| Dec 11 | ASCO GI abstract | Positive | +1.6% | Acceptance of PK/PD sub-study abstract showing decreased systemic drug levels. |
| Aug 14 | Interim DMC & results | Negative | -22.9% | Q2 2025 results, cash update, and DMC recommendation to continue TIGeR-PaC. |
| Apr 29 | Trial enrollment update | Positive | -0.2% | Johns Hopkins joins TIGeR-PaC Phase III trial and enrollment progress update. |
Clinical and trial-related updates have usually aligned with price moves, with one notable sell-off on a mixed clinical/financial update.
Over the last year, RenovoRx has repeatedly highlighted progress around its TAMP™ platform and Phase III TIGeR-PaC program. Events on Apr 29, 2025 and Aug 14, 2025 focused on trial enrollment, interim DMC review, and growing RenovoCath® commercialization. Subsequent news on Dec 11, 2025, Jan 8, 2026, and Jan 28, 2026 emphasized PK/PD data and conference abstracts, often tied to reduced systemic gemcitabine exposure. Today’s SIO 2026 data presentation continues this theme of method refinement and clinical validation for targeted intra-arterial delivery.
Historical Comparison
Clinical-trial tagged news for RNXT has averaged a -1.49% move, suggesting that even constructive trial updates have not consistently driven sustained upside.
Same-tag events trace TIGeR-PaC’s evolution: site activation and enrollment in 2025, positive interim DMC review, and increasingly detailed PK/PD and pressure-monitoring data through ASCO GI and SIO-focused abstracts.
Regulatory & Risk Context
An effective Form S-3 dated Nov 14, 2025 allows RenovoRx to offer up to $50,000,000 of mixed securities over time, and a $3,723,029 at-the-market program via JonesTrading was registered through a 424B5 prospectus. These facilities provide capital-raising flexibility that could be dilutive when used.
Market Pulse Summary
This announcement adds method-focused clinical data to RenovoRx’s TAMP™ platform story, highlighting real-time intra-arterial pressure monitoring ahead of SIO 2026. It follows prior PK/PD findings from TIGeR-PaC and continued enrollment milestones in 2025–2026. At the same time, regulatory filings outline a $50,000,000 shelf and at-the-market program, along with ongoing operating losses. Key watch points include further TIGeR-PaC readouts, commercial traction for RenovoCath, and additional financing activity.
Key Terms
intravascular pressure medical
double balloon catheter medical
trans-arterial micro-perfusion medical
intra-arterial pressure medical
pressure transducer technical
chemotherapy medical
catheter balloon spacing medical
intravascular pressure wire medical
AI-generated analysis. Not financial advice.
Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery
MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that new clinical data will be presented at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting on February 6, 2026.
The clinical data abstract entitled, “Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors,” was led by Christopher Laing, MD of Sutter Health in California. The study explores a simplified method for measuring intra-arterial pressure during procedures that use the TAMP (Trans-Arterial Micro-Perfusion) therapy platform enabled by the RenovoCath catheter, an adjustable, double-balloon drug-delivery device, and how these measurements along with other variables can play a role in optimizing targeted delivery of chemotherapy in difficult-to-treat tumors.
“The ability to measure intra-arterial pressure in real-time provides valuable insight into the mechanics of the approach during TAMP procedures,” said Dr. Laing, MD. “As these techniques are further validated, pressure monitoring has the potential to help clinicians better understand and refine the variables that influence effective drug-delivery.”
Illustration of TAMP delivering chemotherapy near the tumor site via peripheral vascular system
The findings in this study demonstrate that a simplified, external pressure transducer provides reliable and reproducible intra-arterial pressure measurements during TAMP procedures, with strong correlation to intravascular pressure wire measurements in a porcine model. The data further indicates that peak intra-arterial measurements are influenced by controllable procedural variables, including catheter balloon spacing and target vessel diameter, highlighting opportunities for procedural optimization.
Abstract Details:
Presentation Date & Time: Friday, February 6, 2026, at 5:45-6:00 PM ET
Title: Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro Perfusion to Optimize Drug Delivery in Solid Tumors
Location: ePoster Corridor
Abstract Number: 303
Authors: Christopher Laing, Robert Strasser, and Ramtin Agah
Ramtin Agah, RenovoRx’s Chairman and Chief Medical Officer and co-author of the study added, “These findings support the potential for routine intra-arterial monitoring to enhance standardization, optimize delivery conditions, and potentially improve clinical outcomes using our TAMP therapy platform.”
The study is co-authored by a team representing leading academic institutions and cancer centers, including Sutter Health and Atrium Health at the Wake Forest University School of Medicine.
About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. The Company’s mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
RenovoRx is in the early stages of actively commercializing the TAMP therapy platform and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately
RenovoRx is also evaluating a novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
The combination product candidate (IAG), which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the anticipated benefits to the Company of the clinical study abstract described herein, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to commercialize RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial sales efforts for RenovoCath and our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T:212-896-1254
RenovoRx@KCSA.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4e5f6a1a-ac5a-45e5-b856-be46cc42e161
FAQ
When will RenovoRx (RNXT) present TAMP clinical data at SIO 2026?
What did the RNXT study report about pressure monitoring during TAMP procedures?
How could the RNXT TAMP platform's pressure measurements impact chemotherapy delivery?
Does the RNXT abstract demonstrate improved patient outcomes from TAMP therapy?
Who authored the RNXT TAMP study presented at SIO 2026?
